Hudemann B, Riedel H, Seyfarth M, Werner H, Erdmann T
Z Urol Nephrol. 1982 Apr;75(4):253-7.
A report is given on 13 patients with c. i. s. of the bladder, which are examined in vivo and in vitro with respect to their immune reactivity. In skin tests with 5 recall antigens and the primary antigen DNFB there is no difference as compared with a control group of 29 patients. In an EM test 11 of the 13 patients with c. i. s. reacted with histospecific lymphocyte sensitisation, 10 out of 13 positive results were obtained with the antigen HEP. These findings support the current view of c. i. s. of the bladder as the first stage of a malign degeneration.
本文报告了13例膀胱原位癌患者,对其体内和体外的免疫反应性进行了检测。在使用5种回忆抗原和原发性抗原二硝基氟苯(DNFB)进行的皮肤试验中,与29例患者的对照组相比没有差异。在一项EM试验中,13例膀胱原位癌患者中有11例出现组织特异性淋巴细胞致敏反应,13例阳性结果中有10例是使用抗原HEP获得的。这些发现支持了目前将膀胱原位癌视为恶性退变第一阶段的观点。